Skip to main content
SpringerLink
Log in

Glatiramer acetate not associated with adverse pregnancy, foetal, or infant outcomes

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Pregnancy data acquired prior to knowledge of pregnancy outcome or detection of congenital malformation.

Reference

  • Kaplan S, et al. Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding. Drug Safety : 16 Mar 2022. Available from: URL: https://doi.org/10.1007/s40264-022-01168-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Glatiramer acetate not associated with adverse pregnancy, foetal, or infant outcomes. Reactions Weekly 1899, 8 (2022). https://doi.org/10.1007/s40278-022-11982-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-11982-x

Search

Navigation